Investigational drug · Phase 2
TILT-123
Also called: Ad5, 3-E2F-d24-hTNFa-IRES-hIL2
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "TILT-123"
First trial start
2022
May 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TILT-123", any sponsor or status.
Conditions studied
As listed on its trial records.
- Platinum-refractory Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TILT-123" as an intervention, largest first.
TILT Biotherapeutics Ltd.Industry
NCT04695327 · 32 participants · Start Jan 11, 2021 · Primary completion Sep 3, 2025
Drug: TILT-123 · For: Solid Tumor
Sites: Helsinki, Finland · 2 sites in all
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruiting
TILT Biotherapeutics Ltd.Industry
NCT05271318 · 29 participants (planned) · Start May 17, 2022 · Primary completion Mar 2027
Drug: TILT-123; pembrolizumab and 1 more · For: Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma and 6 more
Sites: Rochester, Minnesota; New York, New York; Helsinki, Finland
- Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive, not recruiting
TILT Biotherapeutics Ltd.Industry
NCT06125197 · 22 participants (planned) · Start Jul 23, 2024 · Primary completion Jan 30, 2026
Drug: TILT-123; KEYTRUDA® · For: Lung Cancer
Sites: Newport Beach, California; Santa Monica, California
TILT Biotherapeutics Ltd.Industry
NCT04217473 · 17 participants · Start Feb 26, 2020 · Primary completion Dec 12, 2023
Drug: TILT-123 · For: Metastatic Melanoma
Sites: Copenhagen, Denmark; Nantes, France
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruiting
TILT Biotherapeutics Ltd.Industry
NCT05222932 · 15 participants (planned) · Start Mar 8, 2023 · Primary completion Dec 2026
Drug: TILT-123; Avelumab · For: Melanoma; Head and Neck Squamous Cell Carcinoma
Sites: New York, New York; Helsinki, Finland
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive, not recruiting
TILT Biotherapeutics Ltd.Industry
NCT06961786 · 9 participants (planned) · Start Jun 25, 2025 · Primary completion Nov 2026
Drug: TILT-123; TIL and 2 more · For: Metastatic Melanoma
Sites: Copenhagen, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.
van der Heijden M, Clubb JHA, Erawijantari PP, et al. · Oncoimmunology 2026
- Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.
Shen R, Jin L, Peng X, et al. · Hum Vaccin Immunother 2026
- Combination of live-attenuated and adenovirus-based vaccines provides immediate and durable protection against Yersinia pestis in mice.
Hendrix EK, Sha J, Kilgore PB, et al. · Mol Ther Nucleic Acids 2026
- Effects of COVID-19 vaccination type and vaccination-infection interval on viral clearance dynamics in Omicron BA.5 patients at Guangzhou Fangcang shelter hospitals: A propensity score matched multicenter retrospective cohort study.
Jiang Z, Wang Q, Kong X, et al. · Hum Vaccin Immunother 2026
- Potent neutralization of Rift Valley fever virus mediated by monoclonal antibodies via concurrent inhibition of attachment and fusion.
Hao M, Bian T, Chen Z, et al. · Emerg Microbes Infect 2026
- An engineered Zika virus recombinant adenovirus vaccine induces protective immune response in mice.
Ni H, Chen J, Liu Y, et al. · Microbiol Spectr 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.